Feature | October 26, 2011| Dave Fornell

TAVI ROI Will Come From Surgical Referrals, Not TAVI

The Cardiopulmonary Research Science and Technology Institute (CRSTI) in Dallas, Texas, created two hybrid operating rooms (ORs) specifically for participation in the PARTNER trial for Edwards Sapien transcatheter aortic valve. The center has implanted more than 200 Sapien valves since it started in the trial in 2006.


Angela Riley, RT, CRSTI executive director, said the cost of transcatheter aortic valve implantation (TAVI) and the build out of the hybrid ORs will be prohibitive for most hospitals and the return on investment (ROI) is low. However, she said patients are drawn to facilities offering TAVI.


She said patient selection for TAVI is critical and many patients do not qualify. Her center screens four patients to get one who is suitable for TAVI. Most of those turned away undergo surgical valve replacement. While this is not a good ratio to base return on investment (ROI) for building a TAVI program, Riley said the real returns have come from tripling surgical referrals.


A better strategy to sell the costs of a TAVI program to hospital administrators is not to base ROI on TAVI procedures, but on the increased surgical valve repair volume from the referrals. “Even if patients do not qualify, they will usually stay with your hospital for other treatments,” she explained.

Related Content

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.

News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its...
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association f...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the Coll
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology | February 04, 2021
February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S.

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.